logo
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in Vestis Lawsuit

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in Vestis Lawsuit

NEW YORK - July 22, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Vestis Corporation ('Vestis' or the 'Company') (NYSE: VSTS) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Vestis investors who were adversely affected by alleged securities fraud between May 2, 2024 and May 6, 2025. Follow the link below to get more information and be contacted by a member of our team:
https://zlk.com/pslra-1/vestis-corporation-lawsuit-submission-form?prid=154918&wire=56
VSTS investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Vestis' ability to grow its business; notably that Vestis would be unable to execute on planned strategic initiatives to drive purported improvements to the customer experience and its onboarding efforts in order to drive new customer growth, increased customer retention, and increased revenue from existing customers.On May 7, 2025, Vestis announced its financial results for the second quarter of fiscal 2025, withdrew its revenue and growth guidance for the full fiscal year 2025, and provided guidance for the third quarter of fiscal 2025 that fell significantly below market expectations. The Company attributed its poor results partially to 'lost business in excess of new business,' but primarily on 'lower adds over stops, which is how we describe volume changes with our existing customers.' The Company attributed its decision to pull full-year guidance and provide disappointing third quarter targets to the 'increasingly uncertain macro environment.'Following this news, the price of Vestis' common stock declined dramatically. From a closing market price of $8.71 per share on May 6, 2025, Vestis' stock price fell to $5.44 per share on May 7, 2025, a decline of about 37.54% in the span of just a single day.
WHAT'S NEXT? If you suffered a loss in Vestis during the relevant time frame, you have until August 8, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To learn more about this case, subscribe to the Bulls & Betrayals podcast, which features a dedicated episode unpacking the allegations against Vestis. Listen now and find out if you are eligible to join the lawsuit.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NYSE Content Advisory: Pre-market update + Figma valued at over $19 billion in IPO
NYSE Content Advisory: Pre-market update + Figma valued at over $19 billion in IPO

Yahoo

time2 minutes ago

  • Yahoo

NYSE Content Advisory: Pre-market update + Figma valued at over $19 billion in IPO

NEW YORK, July 31, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on July 31st Equities are catching a bid early Thursday after decent earnings reports from tech giants Microsoft and Meta. Apple and Amazon report their earnings after today's market close. Figma, which provides browser-based design software, raised $1.2 billion after pricing nearly 37 million shares at $33 each. The price was above an upwardly revised range and valued Figma at more than $19 billion. Shoulder Innovations priced five million shares at $15 each in its IPO. The company is a commercial stage shoulder surgery focused Medtech founded in 2009. Opening BellFigma (NYSE: FIG) celebrates its initial public offering Closing BellShoulder Innovations (NYSE: SI) celebrates its initial public offering Click here to download the NYSE TV App View original content to download multimedia: SOURCE New York Stock Exchange Sign in to access your portfolio

Mastercard rises 2% premarket on Q2 earnings, revenue beat
Mastercard rises 2% premarket on Q2 earnings, revenue beat

Yahoo

time2 minutes ago

  • Yahoo

Mastercard rises 2% premarket on Q2 earnings, revenue beat

-- Mastercard shares rose 2% in premarket trading after the payments company posted better-than-expected second-quarter earnings and revenue on the back of robust consumer spending. Adjusted earnings per share came in at $4.15, topping the consensus estimate of $4.03. Revenue for the quarter reached $8.13 billion, ahead of expectations of $7.93 billion. The company said net revenue grew 17% year-over-year, or 16% on a currency-neutral basis, driven by continued growth in consumer spending and cross-border volumes. CEO Michael Miebach highlighted recent business wins, including the extension of its exclusive partnership with American Airlines (NASDAQ:AAL). 'We're well positioned for the opportunities ahead and continue to drive new innovation like the Mastercard (NYSE:MA) Collection and Mastercard Agent Pay,' Miebach said. Related articles Mastercard rises 2% premarket on Q2 earnings, revenue beat These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia If Powell goes, does Fed trust go with him? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Should You Invest in Penumbra (PEN)?
Should You Invest in Penumbra (PEN)?

Yahoo

time2 minutes ago

  • Yahoo

Should You Invest in Penumbra (PEN)?

Baron Funds, an investment management company, released its 'Baron Health Care Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Penumbra, Inc. (NYSE:PEN). Headquartered in Alameda, California, Penumbra, Inc. (NYSE:PEN) designs and manufactures medical devices. The one-month return of Penumbra, Inc. (NYSE:PEN) was 1.25%, and its shares gained 48.44% of their value over the last 52 weeks. On July 30, 2025, Penumbra, Inc. (NYSE:PEN) stock closed at $254.21 per share, with a market capitalization of $9.914 billion. Baron Health Care Fund stated the following regarding Penumbra, Inc. (NYSE:PEN) in its second quarter 2025 investor letter: "We added to our position in Penumbra, Inc. (NYSE:PEN), a medical device company that manufactures mechanical thrombectomy devices to remove clots. We think Penumbra's products are differentiated because of their computer assisted vacuum thrombectomy (CAVT) technology. CAVT utilizes algorithms to modulate the aspiration power depending on if a clot is detected, and to control a separate valve that injects saline to reduce friction between the clot and catheter. This maximizes clot removal while decreasing risk of blood loss. For U.S. thrombectomy, we see a market opportunity for over 1 million procedures a year across stroke and peripheral vascular, with a total addressable market (TAM) north of $8 billion. Of this TAM, Penumbra is only high single digits percentage penetrated in 2024. We are looking forward to this mechanism rolling out in the stroke setting (the Thunderbolt product which is in development). In addition, the company is seeing strong momentum in the venous setting already with their Flash product. We think this momentum could accelerate if the Storm-PE trial, which completed enrollment during the quarter, demonstrates superiority of Penumbra's CAVT plus anticoagulation versus anticoagulation alone (the current standard of care) in intermediate-high risk pulmonary embolism patients. The trial could change the treatment paradigm for pulmonary embolism." A close-up view of a technician wearing protective gloves while installing a mechanical thrombectomy system. Penumbra, Inc. (NYSE:PEN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 47 hedge fund portfolios held Penumbra, Inc. (NYSE:PEN) at the end of the first quarter, which was 35 in the previous quarter. In the second quarter of 2025, Penumbra, Inc. (NYSE:PEN) reported revenue of $339.5 million, marking year-over-year increase of 13.4% on a reported basis and 12.7% on a constant currency basis. While we acknowledge the potential of Penumbra, Inc. (NYSE:PEN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Penumbra, Inc. (NYSE:PEN) and shared the list of best mid-cap healthcare stocks to buy according to hedge funds. Baron Health Care Fund initiated a position in Penumbra, Inc. (NYSE:PEN) during Q1 2025. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store